摘要
隨著臺灣邁入超高齡社會,骨質疏鬆的治療越顯重要。2025年,全民健康保險(National Health Insurance) 擴大給付範圍,納入更多骨折部位並首度核准高風險族群的初級預防,彰顯若能避免骨鬆性骨折的發生,將提升病人的生活品質及醫療上的經濟效益。然而,健保規範與國際治療指引仍存在落差。現行健保將抗骨質再吸收劑列為第一線藥物,但多國的治療指引建議「極高風險族群」應優先使用促骨質生成劑為起始治療,以發揮「基礎效應」快速提升骨密度(bone mineral density),隨後再轉換至抗骨質再吸收劑長期使用以鞏固骨密度。研究指出,若先使用抗骨質再吸收劑,會削弱後續促骨質生成劑的療效;不當的藥物轉換甚至可能導致轉換初期骨密度不增反減。因此在選擇骨質疏鬆治療藥物時,應了解健保給付與臨床指引之落差,評估病人的風險程度後與病人共同討論治療策略,選擇最合適的藥物。骨質疏鬆的治療是一場長期抗戰,因此在治療過程中,常會面臨藥物的轉換,應熟知藥物的特性並密切觀察療效與副作用,妥善規劃藥物的治療順序,以期能達到藥物最好的療效,減少骨鬆性骨折的發生。
ABSTRACT
As society enters a super-aged era, osteoporosis management is increasingly vital. The 2025 expansion of Taiwan’s National Health Insurance (NHI) reimbursement to include additional fracture sites and primary prevention for high-risk groups underscores the importance of fracture prevention for improving patient quality of life and healthcare cost-effectiveness. Nevertheless, a gap remains between NHI regulations and international clinical guidelines. Current NHI criteria prioritize anti-resorptive agents as first-line therapy. In contrast, international guidelines advocate for anabolic agents as the initial treatment for “very high-risk” populations to leverage the “foundation effect” for rapid bone mineral density (BMD) gains before transitioning to long-term anti-resorptive agents for consolidation. Research suggests that prior anti-resorptive use can attenuate the efficacy of subsequent anabolic treatments, and inappropriate drug transitions may lead to paradoxical BMD loss during the initial phase.
Therefore, clinicians must evaluate the discrepancy between reimbursement policies and evidence-based guidelines, performing risk stratification and shared decision-making to select the most appropriate therapy. Managing osteoporosis is a long-term challenge necessitating strategic transition planning. Professionals should understand pharmacological profiles, monitor therapeutic responses and adverse effects, and optimize medication sequencing to achieve maximal efficacy and reduce osteoporotic fracture incidence.
Submitted for publication: 2026.01.16; Accepted for publication: 2026.04.11